Identification of a novel candidate gene,<i>CASC2</i>, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer

Baldinu, Paola; Cossu, Antonio; Manca, Antonella; Satta, Maria Paola; Sini, Maria Cristina; Rozzo, Carla; Dessole, Salvatore; Cherchi, P; Gianfrancesco, Fernando; Pintus, Adriana; Carboni, A.; Deiana, Angelo; Tanda, Francesco; Palmieri, Giuseppe

doi:10.1002/humu.20015

Cited by 89 publications

(77 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[24][25][26][27] However, the expression and functional role of CASC2 in the development of osteosarcoma are still uncovered.…”

mentioning

confidence: 99%

Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR‐181a

Hao

et al. 2017

Cell Proliferation

View full text Add to dashboard Cite

Objectives: Long non-coding RNA cancer susceptibility candidate 2 (CASC2) is a novel lncRNA and has been indicated as playing tumour suppressor gene in several tumours.However, the role of CASC2 in osteosarcoma is still uncovered. Materials and methods:The CASC2 and miR-181a expressions were measured via qRT-PCR. CCK-8 assay and colony formation assay were performed to determine the cell growth, and transwell assay was performed to assess the cell invasion. Results:We showed that CASC2 expression was downregulated in osteosarcoma samples and cell lines. Moreover, we showed that downregulated expression of CASC2 was correlated with advanced TNM stage. Furthermore, overexpression of CASC2 inhibited osteosarcoma cell proliferation, colony formation, and invasion. In addition, we indicated that ectopic expression of CASC2 suppressed miR-181a expression and enhanced the expression of Ras association domain family member 6 (RASSF6), PTEN and ATM in osteosarcoma cell, which were the direct target gene of miR-181a. Moreover, we indicated that RASSF6 expression was downregulated in osteosarcoma samples and cell lines and downregulated expression of RASSF6 was correlated with advanced TNM stage. We found that the expression of RASSF6 was positively correlated with the expression of CASC2 in osteosarcoma tissues. Ectopic expression of CASC2 suppressed the osteosarcoma cell proliferation, colony formation and invasion through regulating RASSF6 expression. Conclusions:Our data illuminated that CASC2 acted as a tumour suppressor in osteosarcoma progression.

show abstract

“…[24][25][26][27] However, the expression and functional role of CASC2 in the development of osteosarcoma are still uncovered.…”

mentioning

confidence: 99%

Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR‐181a

Hao

et al. 2017

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…LncRNA CASC2 was first discovered in 2004 by Baldinu et al [16]. Subsequent studies detected the expression of CASC2 in various types of cancer and found it to be downregulated in cancer tissues as compared with para-cancer or normal samples.…”

Section: Discussionmentioning

confidence: 99%

“…The lncRNA cancer susceptibility candidate 2 (CASC2), located at chromosome 10q26, has been identified as a novel lncRNA that was first found to be downregulated in endometrial cancer [16]. Now increasing numbers of studies have shown that CASC2 is also significantly downregulated in other cancers, such as hepatocellular carcinoma, colorectal cancer, and bladder cancer [17-19], and it could act as a tumor suppressor with implications for diagnosis and therapy [20].…”

Section: Introductionmentioning

confidence: 99%

Low Expression of LncRNA Cancer Susceptibility Candidate 2 and its Clinical Significance in Cancer Tissues

Zhu

Liu

Chen

2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) is downregulated in various cancers and involved in both tumorigenesis and progression. The aim of this study was to assess the prognostic value of lncRNA CASC2 in cancer patients. Methods: We searched the Web of Science, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), and the Wanfang database to identify studies evaluating the prognostic value of lncRNA CASC2 in cancer patients. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed-effects/random-effects models. Results: A total of eight studies were included. The combined results showed that lncRNA CASC2 was significantly associated with decreased overall survival (OS) (HR = 0.37, 95% CI, 0.27–0.46, P < 0.001). Subgroup analyses further indicated that low expression of lncRNA CASC2 predicted decreased OS in cancer patients. Additionally, low CASC2 expression levels in cancer tissues appeared to be correlated with advanced clinical staging (OR = 3.32, 95% CI, 2.29–4.80, P < 0.001). Conclusions: Low CASC2 expression appears to be predictive of poor OS and advanced tumor stage in multiple cancers. CASC2 expression may serve as unfavorable prognostic factor for clinical outcomes in cancer patients.

show abstract

“…16 CASC2 was found to have heterozygosity loss in endometrial carcinoma and differential expression between normal and tumor tissue. 17 hCV11290602 and rs1369 are located in CASC2 intron 1 and 3 0 -UTR, respectively. rs1369, with genotypes distributed independently from those of rs1797, showed a border-line tendency to have higher proportion of heterozygotes among obese men in a subsample (OR ¼ 1.56, 95% CI: 1.00-2.39, 1 df, P ¼ 0.057).…”

Section: Discussionmentioning

confidence: 99%

Association study between chromosome 10q26.11 and obesity among Swedish men

Lavebratt

Şengül

et al. 2005

Int J Obes

View full text Add to dashboard Cite

OBJECTIVE: Proximal chromosome 10q26 was recently linked to waist/hip ratio in European and African-American families. The objective was to investigate whether genomic variation in chromosome 10q26.11 reflects variation in obesity-related clinical parameters in a Swedish population. DESIGN: Genetic association study of single-nucleotide polymorphisms (SNPs) in chromosome 10q26.11 and obesity-related clinical parameters was performed. Obesity was defined as body mass index (BMI)Z30 kg/m 2 . SUBJECTS: Swedish Caucasians comprising 276 obese and 480 nonobese men, 313 obese and 494 nonobese women, 177 obese and 163 nonobese patients with type 2 diabetes mellitus (T2DM), and 106 obese and 201 nonobese subjects with impaired glucose tolerance (IGT) patients. MEASUREMENTS: Genotypes of 11 SNPs at chromosome 10q26.11, and various obesity-related clinical parameters. RESULTS: Homozygosity of a common haplotype constructed by three SNPs, rs2185937, rs1797 and hCV1402327, covering an interval of 2.7 kb, was suggested to confer an increased risk for obesity of 1.5 among men (P ¼ 0.043). The C allele frequency and homozygous genotype frequency of the rs1797 tended to be higher among obese compared to among nonobese men (P ¼ 0.017 and 0.020, respectively). The distribution of BMI and diastolic blood pressure was higher among those with the C/C genotype (P ¼ 0.022 and 0.0061, respectively). The obese and the nonobese groups were homogeneous over BMI subgroups with regard to rs1797 risk genotype distribution. There was no tendency for association between rs1797 and obesity among neither women nor T2DM nor IGT patients. CONCLUSION: We show support for association between proximal chromosome 10q26.11 and obesity among Swedish men but not women through the analysis of a haplotype encompassing 2.7 kb.

show abstract

Identification of a novel candidate gene,CASC2, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer

Cited by 89 publications

References 23 publications

Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR‐181a

Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR‐181a

Low Expression of LncRNA Cancer Susceptibility Candidate 2 and its Clinical Significance in Cancer Tissues

Association study between chromosome 10q26.11 and obesity among Swedish men

Contact Info

Product

Resources

About